Retatrutide dosage: why there is no approved dose yet

Retatrutide is an investigational drug with no FDA approval, so no approved dose exists; this page explains who sets doses in trials, what FDA has said, and the legitimate ways in.

Basics7 min read

Key takeaway

Retatrutide is an investigational drug. FDA says it has "not been found safe and effective for any condition" and cannot be used in compounding under federal law. FDA has warned sellers of research-labeled retatrutide that was sold for human use. The lawful routes to retatrutide are a clinical trial or a physician's expanded access request. Approved alternatives come only through a prescriber.

At a glance

Article typeBasics
Main guideRetatrutide: complete guide
Regulatory statusIn clinical trials“It's in Phase III development under Lilly's TRIUMPH program” (Retatrutide: complete guide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited3 in this article · 16 across 12 articles on Retatrutide
ProductRetatrutide product page

Retatrutide dosage is one of the most searched questions about any peptide. There is no approved dose, because retatrutide is not approved for any use. The doses in Eli Lilly's trials are set by each study's protocol and given under medical monitoring. They are not a guide for anyone outside a trial. This page explains who sets those doses, what FDA has said, and the legitimate ways in. Sources were checked on November 17, 2026.

Quick answer: There is no approved retatrutide dose, and we do not state trial doses. In clinical trials, the protocol sets the doses and investigators monitor every participant. FDA says retatrutide cannot be compounded, and it has warned sellers of research-labeled retatrutide sold for human use. Research-grade retatrutide is a laboratory reagent for laboratory research use only, not for human or veterinary use.

Is there an approved retatrutide dose?

No. FDA says retatrutide is not in any FDA-approved drug and has "not been found safe and effective for any condition" (FDA, 2026). Without an approval there is no FDA label. A label's dosage section is where a reviewed dose would appear (21 CFR 201.57).

Retatrutide, also called LY3437943, is still in Lilly's phase 3 program. For the trial results and what Lilly has said about timing, see our page on retatrutide FDA approval.

Who sets the dose in retatrutide trials?

The sponsor writes the dose plan into the trial protocol before anyone is enrolled. Under FDA rules, each protocol must describe "the method for determining the dose(s) to be administered" and the planned maximum dosage. It must also set out the tests used to monitor the drug's effects and "to minimize risk" (21 CFR 312.23).

The phase 2 trial shows how that works. Participants were screened, then randomly assigned to one of several dose groups defined in the protocol, or to placebo (NCT04881760). Before the trial, its authors wrote that retatrutide's dose-response relationships for "side effects, safety, and efficacy" were not known. They reported that gastrointestinal side effects were dose-related and that heart rate rose in a dose-dependent way (Jastreboff et al., 2023).

In other words, a trial dose is one part of a supervised package. It comes with screening, the sponsor's own manufactured product, scheduled visits, lab tests and investigators watching for side effects. Copying a trial dose without the rest of that package removes the safety net it was designed around.

Why don't online retatrutide dosing charts apply to you?

Online charts lift numbers out of the trials and drop the monitoring. They also assume the product is real retatrutide, at the strength on its label. Neither assumption is safe for material bought outside a trial.

  • Unknown contents. FDA says illegally marketed drugs sold online could contain "the wrong ingredients or harmful ingredients" or "too little, too much or no active ingredient at all" (FDA, 2026).
  • Measured content that did not match the label. A 2024 study tested semaglutide vials bought online without a prescription. The content did not match the label, purity was low, and every sample contained endotoxin (Ashraf et al., 2024).
  • Measuring mistakes. With prescribed compounded semaglutide, FDA received reports of adverse events, some requiring hospitalization, after patients drew up the wrong amount (FDA, 2024).
  • A reported case. A 2026 case report described a man with type 1 diabetes who became seriously ill after using an online product sold as retatrutide. The authors could not establish the cause (Branine, 2026).

Our page on the risks of using research peptides on yourself covers these problems in more detail.

What has FDA said about unapproved and compounded retatrutide?

FDA states that retatrutide and cagrilintide "cannot be used in compounding under federal law" (FDA, 2026). FDA has warned telehealth companies for marketing retatrutide and ingredient distributors for selling it to compounders. It has also warned outsourcing facilities for repackaging it.

FDA has also warned companies that sold retatrutide and other GLP-1 products "falsely labeled" for research purposes. It says these products "have been sold directly to consumers for human use with dosing instructions" (FDA, 2026). FDA urges consumers not to buy them, calling them "of unknown quality" and possibly harmful. Table 1 lists warning letters we read on fda.gov.

Table 1

FDA warning letters involving retatrutide (read November 17, 2026)

Date Who FDA wrote to What FDA found Letter
December 10, 2024 An online seller of research-labeled GLP-1 products Despite "research use only" labels, website evidence showed the products were "intended to be drugs for human use" FDA
September 9, 2025 An online seller of compounded drugs Compounded retatrutide met none of the 503A conditions and was not on the 503B bulks list FDA
March 31, 2026 An online seller using a code name for retatrutide Products labeled "laboratory research purposes only" were found to be drugs FDA
August 24, 2026 An online seller of research-labeled peptides Despite "not for human or veterinary use" labels, website evidence showed the products were "intended to be drugs for human use" FDA

The legal point is intended use. FDA judges it from labeling, advertising and the circumstances of sale, not from a label alone (21 CFR 201.128). A "research use only" label does not, by itself, make it legal to sell or use retatrutide for people. Our page on whether retatrutide is legal covers the full picture.

How can you get retatrutide legitimately?

  • A clinical trial. Lilly's trials are registered on ClinicalTrials.gov, where each record shows its status and who can join. Our guide on how to find a peptide clinical trial walks through the search.
  • Expanded access. Lilly lists a pre-approval expanded access program for individual patients. It is limited to adults with severe obesity who meet strict criteria and cannot join a trial (NCT07629401). A licensed physician files the request, and the company must agree to supply the drug (FDA).
  • An approved medicine. FDA has approved other medicines for chronic weight management, including Wegovy and Zepbound (DailyMed). Only a prescriber can decide whether any of them fits you. See how their doses are set.

If something goes wrong after using any product sold as retatrutide, call 911 in an emergency. Poison Help at 1-800-222-1222 is free, confidential and open 24 hours a day (MedlinePlus, 2025). Tell your clinician exactly what you used. You can report the problem to FDA through MedWatch or 1-888-INFO-FDA (1-888-463-6332), option 2. Our page on retatrutide side effects covers what the trials reported.

Frequently asked questions about retatrutide dosage

What is the retatrutide dose?

There is no approved retatrutide dose, because FDA has not approved retatrutide for any use. In trials, each protocol sets the doses and investigators monitor every participant.

Is there a retatrutide dosing chart?

No official one exists. Charts online copy trial numbers without the screening and monitoring that came with them, and FDA has not reviewed them.

Who sets the dose in retatrutide trials?

The sponsor sets it in the trial protocol, which FDA rules require to describe how doses are chosen and how participants are monitored. Investigators then follow that protocol for each participant.

How much bacteriostatic water do you mix with retatrutide?

We do not give mixing or reconstitution instructions. Retatrutide has no approved product or label, and research-grade retatrutide is for laboratory research only, not for human or veterinary use.

Where do you inject retatrutide?

We do not give injection instructions. Retatrutide has no FDA label, and in trials the study team gives instructions under the protocol.

Can a doctor prescribe retatrutide?

Not as a prescription, because there is no approved product and FDA says it cannot be compounded. A physician can refer you to a trial or request expanded access for an eligible patient.

What to know now

  • Approved dose: none; retatrutide is not FDA-approved for any use.
  • Trial doses: set by each protocol and given under investigator monitoring.
  • Compounding: FDA says retatrutide cannot be compounded under federal law.
  • Enforcement: FDA warning letters looked past research-use labels when sellers marketed retatrutide for people.
  • Legitimate routes: a clinical trial or physician-requested expanded access; approved alternatives only through a prescriber.
  • Research grade: a laboratory reagent, not for human or veterinary use.

What we're watching

Whether Lilly files retatrutide with FDA on its stated timeline, any FDA approval and the label that would come with it, and new FDA warning letters about retatrutide sold for human use.

Also in the library

More for endocrine & metabolism

All 41 compounds for endocrine & metabolism

Sources: U.S. Food and Drug Administration 2026, FDA's concerns with unapproved GLP-1 drugs used for weight loss; Code of Federal Regulations. 21 CFR 312.23: IND content and format . https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.23, 21 CFR 312.23: IND content and format; Code of Federal Regulations. 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products . https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201.57; Code of Federal Regulations. 21 CFR 201.128: Meaning of "intended uses" . https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-E/section-201.128, 21 CFR 201.128: Meaning of "intended uses"; Jastreboff 2023, New England Journal of Medicine; ClinicalTrials.gov. NCT04881760: A phase 2 study of LY3437943 in participants who have obesity or are overweight . https://clinicaltrials.gov/study/NCT04881760; ClinicalTrials.gov. NCT07629401: Pre-approval expanded access of retatrutide (LY3437943) . https://clinicaltrials.gov/study/NCT07629401, NCT07629401: Pre-approval expanded access of retatrutide (LY3437943); U.S. Food and Drug Administration 2024, Expanded access: information for physicians; U.S. Food and Drug Administration 2024, Warning letter to an online seller of research-labeled GLP-1 products, MARCS-CMS 695607; U.S. Food and Drug Administration 2025, Warning letter about compounded retatrutide, MARCS-CMS 716459; U.S. Food and Drug Administration 2026, Warning letter about research-labeled GLP-1 products, MARCS-CMS 721805; U.S. Food and Drug Administration 2026, Warning letter about research-labeled peptides, MARCS-CMS 735067; Ashraf 2024, Journal of Medical Internet Research; Branine 2026, Cureus; U.S. Food and Drug Administration 2024; National Library of Medicine. DailyMed: Zepbound (tirzepatide), DailyMed: Zepbound (tirzepatide), Eli Lilly and Company; National Library of Medicine 2025, MedlinePlus: Poison control center, emergency number; U.S. Food and Drug Administration 2025, Reporting serious problems to FDA. All 18 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  2. Code of Federal Regulations. 21 CFR 312.23: IND content and format. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.23
  3. Code of Federal Regulations. 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201.57
  4. Code of Federal Regulations. 21 CFR 201.128: Meaning of "intended uses". https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-E/section-201.128
  5. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 389(6), 514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
  6. ClinicalTrials.gov. NCT04881760: A phase 2 study of LY3437943 in participants who have obesity or are overweight. https://clinicaltrials.gov/study/NCT04881760
  7. ClinicalTrials.gov. NCT07629401: Pre-approval expanded access of retatrutide (LY3437943). https://clinicaltrials.gov/study/NCT07629401
  8. U.S. Food and Drug Administration. (2024). Expanded access: information for physicians. https://www.fda.gov/news-events/expanded-access/expanded-access-information-physicians
  9. U.S. Food and Drug Administration. (2024, December 10). Warning letter to an online seller of research-labeled GLP-1 products, MARCS-CMS 695607. FDA warning letter on fda.gov
  10. U.S. Food and Drug Administration. (2025, September 9). Warning letter about compounded retatrutide, MARCS-CMS 716459. FDA warning letter on fda.gov
  11. U.S. Food and Drug Administration. (2026, March 31). Warning letter about research-labeled GLP-1 products, MARCS-CMS 721805. FDA warning letter on fda.gov
  12. U.S. Food and Drug Administration. (2026, August 24). Warning letter about research-labeled peptides, MARCS-CMS 735067. FDA warning letter on fda.gov
  13. Ashraf, A. R., Mackey, T. K., Vida, R. G., et al. (2024). Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. Journal of Medical Internet Research, 26, e65440. https://pubmed.ncbi.nlm.nih.gov/39509151/
  14. Branine, N. (2026). Online-sourced retatrutide complicating impending diabetic ketoacidosis in a patient with type 1 diabetes and concurrent Shigella gastroenteritis. Cureus, 18(8), e115260. https://pubmed.ncbi.nlm.nih.gov/42669023/
  15. U.S. Food and Drug Administration. (2024). FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  16. National Library of Medicine. DailyMed: Zepbound (tirzepatide), Eli Lilly and Company. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  17. National Library of Medicine. (2025). MedlinePlus: Poison control center, emergency number. https://medlineplus.gov/ency/article/002724.htm
  18. U.S. Food and Drug Administration. (2025). Reporting serious problems to FDA. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda